We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
This study shows that the two long-term cholinesteraseinhibitor treatments exert different effects on biological markers for AD.
2
Background: There have been very limited investigations of cholinesteraseinhibitor therapy in more advanced stages of Alzheimer's disease (AD).
3
All patients who entered the trial had previously failed to respond to a structurally related cholinesteraseinhibitor without adrenergic properties (HP 029).
4
Treatment with oral cholinesteraseinhibitors produced a dramatic improvement in muscle strength.
5
Complex interactions between the effects of local and systemic cholinesteraseinhibitors were observed.
Usage of cholinesterase inhibitors in inglês
1
Treatment with oral cholinesteraseinhibitors produced a dramatic improvement in muscle strength.
2
Complex interactions between the effects of local and systemic cholinesteraseinhibitors were observed.
3
Avoid contact with carbamate or organo-phosphate insecticides and pesticides while using cholinesteraseinhibitors.
4
These findings may have an important influence on the way cholinesteraseinhibitors are prescribed.
5
This review presents the main classes of cholinesteraseinhibitors developed recently for the treatment of AD.
6
These results suggest that there are significant differences in the mechanisms of action of various cholinesteraseinhibitors.
7
Among various attempts to enhance cholinergic neurotransmission in AD clinical trials with cholinesteraseinhibitors have been most promising.
8
Increase in cerebral glucose metabolism has also been measured following fairly long periods of treatment with cholinesteraseinhibitors (months).
9
If you are taking cholinesteraseinhibitors to control it, using topical cholinesteraseinhibitors puts you at greater risk for adverse effects.
10
The first group of patients received only the drug while the second group received cholinesteraseinhibitors in addition to MEM 1003.
11
Identification of LGM with TAs among patients with congenital myasthenic syndrome is important because treatment with cholinesteraseinhibitors can produce symptomatic improvement.
12
An improvement of the nicotinic receptors has been found in cortical regions following treatment with cholinesteraseinhibitors and nerve growth factors (NGF) to AD patients.
13
Results were analyzed according to the duration of therapy with acetyl- cholinesteraseinhibitors (ACHEI) and to the timing of the beginning with respect to the diagnosis.
14
Cholinesteraseinhibitors used to treat Alzheimer's
15
Cholinesteraseinhibitors are effective treatments for dementia in PD, but improvement is modest and motor side effects may occur.
16
Cholinesteraseinhibitors are a group of drugs prescribed to treat symptoms resulting from the early and middle stages of Alzheimer disease.